Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 8/20 | 0.78 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1905449 | 0.96 | STAT3 (0.84) | STAT3MCL1LMNAKDM4EMEN1 | |
| SCHEMBL1900395 | 0.94 | STAT3 (0.82) | STAT3MCL1LMNAKDM4EMEN1 | |
| SCHEMBL1899829 | 0.92 | STAT3 (0.77) | STAT3MCL1LMNAKDM4EMEN1 | |
| SCHEMBL1897879 | 0.92 | STAT3 (0.77) | STAT3MCL1LMNAKDM4EMEN1 | |
| SCHEMBL1899563 | 0.92 | STAT3 (0.89) | STAT3LMNAKDM4EMEN1HTT | |
| SCHEMBL1900515 | 0.89 | STAT3 (0.74) | STAT3MCL1 | |
| SCHEMBL1899741 | 0.88 | STAT3 (0.73) | STAT3MCL1LMNAKDM4EMEN1 | |
| SCHEMBL29382140 | 0.88 | STAT3 (1.00) | STAT3LMNAKDM4EMEN1HTT | |
| SCHEMBL1899809 | 0.88 | STAT3 (1.00) | STAT3LMNAKDM4EMEN1HTT | |
| SCHEMBL1897448 | 0.87 | STAT3 (0.81) | STAT3LMNAKDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218693-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-07-14 | — | — | US | disclosed |
| EP-3960199-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | Kabushiki Kaisha Yakult Honsha (JP) | 2022-03-02 | — | — | EP | disclosed |
| US-20220008409-A1 | CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3854397-A1 | CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | Kabushiki Kaisha Yakult Honsha (JP) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020059705-A1 | CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | 株式会社ヤクルト本社 | 2020-03-26 | — | — | WO | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008409-A1 | CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | JAK2, ROS1, ABL1 | STAT3 14/4885MCL1 279/4885LMNA 4862/4885 |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | STAT3 1/4885MCL1 2785/4885LMNA 4766/4885 |
| US-20220218693-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | STAT3, PDCD1, CD274 | STAT3 1/4885MCL1 384/4885LMNA 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.